The Problem of Economic Availability of Anticoagulants in COVID-19 Outpatient Treatment

Vinogradova A. D.
Postgraduate, Chair for Management and Economics of Pharmacy with courses in pharmacognosy, pharmaceutical technology, pharmaceutical and toxicological chemistry¹

Demidova M. A.
Doctor of Medicine, Professor, Head, Chair for Management and Economics of Pharmacy with courses in pharmacognosy, pharmaceutical technology, pharmaceutical and toxicological chemistry¹

1 - Tver State Medical University

Vinogradova Angela; e-mail: an.vino97@mail.ru

None declared.

The study had no sponsorship.

An assessment of the economic availability of direct oral anticoagulants for COVID-19 outpatient treatment was carried out. For each anticoagulant, the average cost of the package and treatment course were determined, the coefficients of availability in relation to the average wage and the minimum living wage were calculated. Based on the results of the study, an ABC analysis was carried out. The costs of dabigatran, apixaban and rivaroxaban were found to be in category A (high cost) in relation to the minimum living wage. The most accessible of the investigated anticoagulants is apixaban 5 mg in a package of 60 tablets, the coefficient of availability of this drug in relation to the average wage was 21.7, in relation to the living wage – 66.1. The low availability of anticoagulants for the course treatment of COVID-19 in outpatient settings justifies the need for the formation of drug programs for COVID-19 outpatient with at the expense of the federal budget.

economic availability, anticoagulants, COVID-19

10.29234/2308-9113-2021-9-4-21-30

1. Schiavone M., Gasperetti A., Mancone M. et al. Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience. Int J Cardiol. 2021; 323: 276-280. doi: 10.1016/j.ijcard.2020.09.001.

2. Gautret P., Million M., Jarrot P.A. et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020; 16(12): 1159-1184. doi: 10.1080/1744666X.2021.1847640.

3. Rico-Mesa J.S., Rosas D., Ahmadian-Tehrani A. et al. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Curr Cardiol Rep. 2020; 22(7): 53. doi: 10.1007/s11886-020-01328-8.

4. Moreno G., Carbonell R., Bodí M., Rodríguez A. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva. 2021; 45(1): 42-55. doi: 10.1016/j.medin.2020.06.006.

5. McCullough P.A., Kelly R.J., Ruocco G. et al. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2021; 134(1): 16-22. doi: 10.1016/j.amjmed.2020.07.003.

6. Costanzo L., Palumbo F.P., Ardita G. et al; Italian Society for Vascular Investigation and the Italian Society of Vascular Medicine. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. J Vasc Surg Venous Lymphat Disord. 2020; 8(5): 711-716. doi: 10.1016/j.jvsv.2020.05.018.

7. Vinogradova A.D., Malygin A.S., Demidova M.A. Antikoagulyanty v klinicheskoj praktike: obzor literatury. [Anticoagulants in medical practice: literature review]. Verkhnevolzhsky Medical Journal [Upper Volga Medical Journal] 2020; 19(4): 27-31. (In Russ.)

8. Ujeyl M., Köster I., Wille H. et al. Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. Eur J Clin Pharmacol. 2018; 74(10): 1317-1325. doi: 10.1007/s00228-018-2504-7.

9. Hur M., Park S.K., Koo C.H. et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. Acta Orthop. 2017; 88(6): 634-641. doi: 10.1080/17453674.2017.1361131.

10. Postanovlenie Pravitel'stva Rossijskoj Federacii ot 04.02.2021 № 110 «Ob utverzhdenii Pravil predostavleniya v 2021 godu inyh mezhbyudzhetnyh transfertov, imeyushchih celevoe naznachenie, iz federal'nogo byudzheta byudzhetam sub»ektov Rossijskoj Federacii i byudzhetu g. Bajkonura, istochnikom finansovogo obespecheniya kotoryh yavlyayutsya byudzhetnye assignovaniya rezervnogo fonda Pravitel'stva Rossijskoj Federacii, v celyah sofinansirovaniya raskhodnyh obyazatel'stv sub«ektov Rossijskoj Federacii i g. Bajkonura po finansovomu obespecheniyu meropriyatij po priobreteniyu lekarstvennyh preparatov dlya lecheniya pacientov s novoj koronavirusnoj infekciej (COVID-19), poluchayushchih medicinskuyu pomoshch' v ambulatornyh usloviyah». [Resolution of the Government of the Russian Federation of 04.02.2021 № 110 «On Approval of the Rules for the Provision in 2021 of Other Inter-budgetary Transfers with a Purpose from the Federal Budget to the Budgets of the Subjects of the Russian Federation and the Budget of Baikonur, the source of financial support for which are budgetary allocations of the Reserve Fund of the Government of the Russian Federation, in order to co-finance the expenditure obligations of the subjects of the Russian Federation and the city of Baikonur for the financial support of measures for the purchase of medicines for the treatment of patients with a new coronavirus infection (COVID-19) receiving medical care on an outpatient basis»]. Available at: http://publication.pravo.gov.ru/Document/View/0001202102050033 (accessed: 21.10.2021). (In Russ.)

11. Vremennye metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya 13. 2021. [Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 13. 2021.] Available at: https://minzdrav.gov.ru (accessed: 1.10.2021). (In Russ.)

12. Federal'naya sluzhba gosudarstvennoj statistiki [Federal State Statistics Service] Available at: https://rosstat.gov.ru (accessed: 30.09.2021). (In Russ.)

13. Postanovlenie Pravitel'stva Rossijskoj Federacii ot 30.10.2020 g. № 1763 «Ob utverzhdenii Pravil predostavleniya v 2020 godu inyh mezhbyudzhetnyh transfertov iz federal'nogo byudzheta byudzhetam sub»ektov Rossijskoj Federacii, istochnikom finansovogo obespecheniya kotoryh yavlyayutsya byudzhetnye assignovaniya rezervnogo fonda Pravitel'stva Rossijskoj Federacii, v celyah finansovogo obespecheniya meropriyatij po priobreteniyu lekarstvennyh preparatov dlya lecheniya pacientov s novoj koronavirusnoj infekciej (COVID-19), poluchayushchih medicinskuyu pomoshch' v ambulatornyh usloviyah«. [Resolution of the Government of the Russian Federation № 1763 of 10.30.2020 »On Approval of the Rules for the Provision in 2020 of Other Inter-budgetary Transfers from the Federal Budget to the Budgets of the Constituent Entities of the Russian Federation, the Source of Financial Support for which are budgetary Allocations of the Reserve Fund of the Government of the Russian Federation, in order to financially support measures for the purchase of medicines for the treatment of patients with a new coronavirus infection (COVID-19) receiving medical care on an outpatient basis«]. Available at: http://government.ru/docs/all/130686/ (accessed: 21.10.2021). (In Russ.)